235 related articles for article (PubMed ID: 32000436)
1. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Garcovich S; Giovanardi G; Malvaso D; De Simone C; Peris K
Medicine (Baltimore); 2020 Jan; 99(5):e18991. PubMed ID: 32000436
[TBL] [Abstract][Full Text] [Related]
2. Off-label studies on apremilast in dermatology: a review.
Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
[No Abstract] [Full Text] [Related]
3. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
[TBL] [Abstract][Full Text] [Related]
4. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
5. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Vossen ARJV; van Doorn MBA; van der Zee HH; Prens EP
J Am Acad Dermatol; 2019 Jan; 80(1):80-88. PubMed ID: 30482392
[TBL] [Abstract][Full Text] [Related]
6. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
[TBL] [Abstract][Full Text] [Related]
7. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A
Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196
[TBL] [Abstract][Full Text] [Related]
8. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
Weber P; Seyed Jafari SM; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2017 Jun; 76(6):1189-1191. PubMed ID: 28522043
[No Abstract] [Full Text] [Related]
9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
10. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
11. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
Aarts P; Vossen ARJV; van der Zee HH; Prens EP; van Straalen KR
J Am Acad Dermatol; 2021 Jul; 85(1):258-260. PubMed ID: 32891782
[No Abstract] [Full Text] [Related]
13. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
14. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
[TBL] [Abstract][Full Text] [Related]
15. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
17. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Schafer PH; Chen P; Fang L; Wang A; Chopra R
J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
19. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Gisondi P; Girolomoni G
Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
